GoodRx Q2 2023 Earnings Report
Key Takeaways
GoodRx's second quarter 2023 results exceeded expectations, with revenue at $189.7 million. Prescription transactions revenue and volume returned to year-over-year growth. The company is focused on rebuilding momentum financially and operationally, aiming for growth in 2024 and beyond.
Total revenue of $189.7 million, exceeding previously announced guidance
Net income of $58.8 million with a net income margin of 31.0%
Adjusted EBITDA of $53.5 million with an Adjusted EBITDA Margin of 28.2%, exceeding previously announced guidance
Over 500,000 prescribers engaged with GoodRx through Provider Mode since its launch
GoodRx
GoodRx
Forward Guidance
GoodRx is guiding to third quarter revenue in the range of $186 million to $190 million and Adjusted EBITDA Margin in the mid-to-high twenty-percent range. In the back half of this year, GoodRx will continue to balance business imperatives for 2024 and beyond with immediate results.